Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1

被引：6
作者：
Huang, Tao [1 ]
Gong, Wei-Hua [2 ]
Li, Xiu-Cheng [1 ]
Zou, Chun-Ping [1 ]
Jiang, Guang-Jian [2 ]
Li, Xu-Hui [2 ]
Qian, Hao [1 ]
机构：
[1] China Med Univ, Affiliated Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2012年 / 13卷 / 07期
关键词：
Osteosarcoma; TRAIL; oxaliplatin; apoptosis; OSTEOSARCOMA CELLS; TARGETING MCL-1; UP-REGULATION; TUMOR-CELLS; EXPRESSION; COMBINATION; RESISTANCE; TOXICITY; LINES;
D O I：
10.7314/APJCP.2012.13.7.3477
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: To investigate the killing effect on OS cells of a combination of oxaliplatin and TRAIL and related molecular mechanisms. Methods: TRAIL and oxaliplatin were applied to OS732 cells singly or jointly and survival inhibition rates were measured by MTT assay, changes of cellular shape being assessed with inverted phase contrast and fluorescence microscopy. Apoptotic rates were analyzed by flow cytometry (FCM) and immunocytochemistry was used to examine Mcl1 expression of OS732 cells. Results: The survival inhibition rate of combined application of 100 mu g/ml TRAIL and 1 mu g/ml oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p<0.01). Changes of cellular shape and apoptotic rates also indicated apoptosis-inducing effects of combined application to be much stronger than those of individual application. Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis. Conclusion: A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.
引用
收藏
页码：3477 / 3481
页数：5
相关论文
共 28 条
[1]   The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity [J].
Arlt, Matthias J. E. ;
Walters, Denise K. ;
Banke, Ingo J. ;
Steinmann, Patrick ;
Puskas, Gabor J. ;
Bertz, Josefine ;
Rentsch, Katharina M. ;
Ehrensperger, Felix ;
Born, Walter ;
Fuchs, Bruno .
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) :E804-E812
[2]   A Phase II Trial and Pharmacokinetic Study of Oxaliplatin in Children With Refractory Solid Tumors: A Children's Oncology Group Study [J].
Beaty, Orren, III ;
Berg, Stacey ;
Blaney, Susan ;
Malogolowkin, Marcio ;
Krailo, Mark ;
Knight, Ronald ;
Schaiquevich, Paula ;
Stewart, Clinton ;
Chen, Zhengjia ;
Nelson, Marvin ;
Voss, Stephan ;
Ivy, S. Percy ;
Adamson, Peter C. .
PEDIATRIC BLOOD & CANCER, 2010, 55 (03) :440-445
[3]   Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy [J].
Bouralexis, S ;
Findlay, DM ;
Atkins, GJ ;
Labrinidis, A ;
Hay, S ;
Evdokiou, A .
BRITISH JOURNAL OF CANCER, 2003, 89 (01) :206-214
[4]   On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy [J].
Bruland, OS ;
Pihl, A .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1725-1731
[5]  
Brunat-Mentigny M, 1993, Rev Prat, V43, P2197
[6]   Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow Osteosarcoma in mice:: a mathematical model. [J].
Clairambault, J ;
Claude, D ;
Filipski, E ;
Granda, T ;
Lévi, F .
PATHOLOGIE BIOLOGIE, 2003, 51 (04) :212-215
[7]   Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL Through JNK-Dependent Phosphorylation of Bcl-xL [J].
El Fajoui, Zineb ;
Toscano, Florent ;
Jacquemin, Guillaume ;
Abello, Jacques ;
Scoazec, Jean-Yves ;
Micheau, Olivier ;
Saurin, Jean-Christophe .
GASTROENTEROLOGY, 2011, 141 (02) :663-673
[8]   Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies [J].
Geoerger, Birgit ;
Doz, Francois ;
Gentet, Jean-Claude ;
Mayer, Michele ;
Landman-Parker, Judith ;
Pichon, Fabienne ;
Chastagner, Pascal ;
Rubie, Herve ;
Frappaz, Didier ;
Le Bouil, Anne ;
Gupta, Sunil ;
Vassal, Gilles .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) :4394-4400
[9]   Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors [J].
Gores, Gregory J. ;
Kaufmann, Scott H. .
GENES & DEVELOPMENT, 2012, 26 (04) :305-311
[10]   Oxaliplatin, Irinotecan, and Gemcitabine: A Novel Combination in the Therapy of Progressed, Relapsed, or Refractory Tumors in Children [J].
Hartmann, Carolin ;
Weinel, Peter ;
Schmid, Hansjoerg ;
Grigull, Lorenz ;
Sander, Anette ;
Linderkamp, Christin ;
Welte, Karl ;
Reinhardt, Dirk .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (05) :344-349
123